Catalyst Dossier · compiled by CeliA 🧫

Indivior PLC (INDV.L)

Pharmaceutical Preparations · market cap $2.3B

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
SUBOXONE	Phase 3	Opioid Dependence
XP19986 CR	Phase 2	GERD
RBP-7000	Phase 3	Schizophrenia
INDV-6001	Phase 2	Moderate to Severe Opioid Use Disorder
INDV-2000	Phase 2	Opioid Use Disorder
SUBOXONE sublingual film	Phase 3	Opioid Use Disorder
RBP-6300	Phase 2	Opioid Related Disorder
Buprenorphine hydrochloride marketed sublingual tablet (Subutex)	Phase 2	Opioid Dependency
RBP-6000	Phase 3	Opioid Use Disorder
Arbaclofen Placarbil	Phase 2	Alcohol Use Disorder
Risperidone	Phase 2	Schizophrenia
Subutex	Phase 2	Opioid Related Disorder
Buprenorphine soluble film	Phase 2	Opioid-related Disorders
Buprenorphine	Phase 2	Opioid Use Disorder
RBP-8000 100 mg	Phase 2	Opioid Dependence
Buprenorphine/naloxone Film Strip	Phase 2	Opioid-Related Disorders

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for INDV.L (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 16 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.